ABIONYX Pharma S.A.
ABNX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €42,306 | €41,266 | €37,680 | €40,209 |
| - Cash | €3,375 | €3,235 | €5,304 | €4,104 |
| + Debt | €4,118 | €2,757 | €3,171 | €3,390 |
| Enterprise Value | €43,049 | €40,788 | €35,547 | €39,495 |
| Revenue | €2,120 | €2,256 | €2,344 | €2,512 |
| % Growth | -6% | -3.8% | -6.7% | – |
| Gross Profit | €230 | €597 | €303 | €629 |
| % Margin | 10.8% | 26.5% | 12.9% | 25% |
| EBITDA | -€2,278 | €2,051 | -€2,291 | -€1,137 |
| % Margin | -107.4% | 90.9% | -97.7% | -45.3% |
| Net Income | -€2,300 | -€2,293 | -€2,088 | -€1,270 |
| % Margin | -108.5% | -101.6% | -89.1% | -50.6% |
| EPS Diluted | -0.067 | -0.066 | -0.065 | -0.041 |
| % Growth | -0.6% | -2% | -59.2% | – |
| Operating Cash Flow | -€1,700 | -€1,726 | -€1,874 | -€1,159 |
| Capital Expenditures | -€162 | €23 | -€23 | -€36 |
| Free Cash Flow | -€1,700 | -€1,703 | -€1,897 | -€1,195 |